National investment loss lawyers KlaymanToskes is investigating Gregory Iglow of Oppenheimer & Co. Inc. (CRD #2783963).
Gregory Iglow, a broker registered with Oppenheimer & Co. Inc. in Los Angeles, California since 2007, is currently under investigation for allegations of unsuitable investment recommendations, with recent complaints accusing him of negligence, violations of state securities laws, fraud, breach of fiduciary duty, and breach of contract, with one claimant seeking $3,000,000 in damages and another seeking $231,826 in damages, both cases are currently pending.
Investors that suffered losses with Gregory Iglow (Oppenheimer & Co. Inc.) are encouraged to contact attorney Lawrence L. Klayman, Esq., at 888-997-9956 or by email at lawrence@klaymantoskes.com to discuss recovery options. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.
Broker Gregory Iglow is currently facing two significant customer complaints, as per his CRD report. These complaints, filed in March and May 2023, allege serious violations, including unsuitability, negligence, and breach of contract, among others.
These are the latest in a series of nine complaints lodged against Iglow between 2003 and 2023. The May 2023 complaint alleges that the claimant suffered substantial losses due to unsuitable investments. The claimant accuses Iglow of violating state securities laws, negligence, unsuitability, fraud, breach of fiduciary duty, and breach of contract related to the claimant’s bond purchases between September 2018 and the present. The claimant is seeking a hefty $3,000,000 in damages, and the case is still under consideration. The March 2023 complaint is also based on allegations of negligence and unsuitability. The claimants contend that Iglow violated California Securities Law, FINRA Rules, and Federal Securities Laws. They also accuse him of breach of contract and negligent supervision in connection with their purchases of Capital Trust Agency Florida Senior Living Bonds in 2019 and 2020. The claimants are seeking $231,826 in damages, and this case is also currently pending.
According to the rules established by the Financial Industry Regulatory Authority (FINRA), member firms are accountable for supervising a broker’s activities while the broker is registered with the firm. As a result, Oppenheimer & Co. Inc., the firm with which Iglow is registered, could potentially be held liable for investment or other losses suffered by Iglow’s customers.
Gregory Iglow has been a broker for Oppenheimer & Co. Inc. since 2007, has been subject to nine customer complaints, two of which were denied and one was withdrawn. Currently, Iglow has two complaints for negligence/unsuitability, violations of California securities law, violations of FINRA rules and federal securities laws, breach of contract, negligent supervision, respondent superior, and breach of
As an investor, there are a few signs that you should look out for if you believe you may have a claim against Gregory Iglow. These signs could potentially indicate misconduct, negligence, or investment fraud. Investors are encourage to contact our firm immediately if you have experienced any of the following:
Some investors have close relationships with their brokers due to the time and trust built over the course of their investment relationship. However, it is crucial to remember that financial decisions should be based on careful analysis and due diligence rather than solely relying on personal relationships.
Engaging the services of an experienced securities attorney to evaluate your specific circumstances is strongly advised. At KlaymanToskes, our team of experienced securities attorneys has a deep understanding of this complex area of law, allowing us to provide invaluable insight and tailored guidance that directly addresses your individual needs.
If you suffered losses with Gregory Iglow, or have concerns regarding your investment portfolio at Oppenheimer & Co. Inc., contact KlaymanToskes at 888-997-9956 or fill out a short contact form for a free and confidential consultation.